BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia

  September 23, 2024

   · 

  2 min read
• Press Releases

  Samsung Bioepis Presents Totality-of-the-Evidence Supporting Extrapolation of EPYSQLI™ (SB12; Eculizumab)’s Indication, at the European Society of Paediatric Nephrology (ESPN) 2024

  September 23, 2024

   · 

  7 min read
• Press Releases

  Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

  September 23, 2024

   · 

  4 min read
• Press Releases

  Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

  September 23, 2024

   · 

  5 min read
• Press Releases

  Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

  September 23, 2024

   · 

  1 min read
• Press Releases

  European Commission Approves LEO Pharma’s Anzupgo® (delgocitinib) Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE)

  September 23, 2024

   · 

  9 min read
• Press Releases

  FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema

  September 23, 2024

   · 

  10 min read
• Press Releases

  Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

  September 23, 2024

   · 

  4 min read
• Press Releases

  uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

  September 23, 2024

   · 

  5 min read
• Press Releases

  Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

  September 23, 2024

   · 

  7 min read